KIF24

Summary

KIF24 (kinesin family member 24, HGNC:19916) is a protein-coding gene on chromosome 9p13.3, encoding Kinesin-like protein KIF24 (Q5T7B8). Microtubule-dependent motor protein that acts as a negative regulator of ciliogenesis by mediating recruitment of CCP110 to mother centriole in cycling cells, leading to restrict nucleation of cilia at centrioles.

This gene encodes a member of the kinesin superfamily of microtubule-based motor proteins which are involved in the intracellular transport of membranous organelles, protein complexes, and mRNAs. They also play critical roles in mitosis, morphogenesis, and signal transduction. The encoded protein contains an N-terminal sterile alpha motif (SAM) domain and an ATP-binding kinesin motor domain. It binds centriolar coiled coil protein 110 and centrosomal protein 97 and localizes to the mother centriole to regulate ciliogenesis by controlling microtubule polymerization.

Source: NCBI Gene 347240 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 224 total — 2 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_194313

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19916
Approved symbol	KIF24
Name	kinesin family member 24
Location	9p13.3
Locus type	gene with protein product
Status	Approved
Aliases	bA571F15.4, FLJ10933, FLJ43884
Ensembl gene	ENSG00000186638
Ensembl biotype	protein_coding
OMIM	613747
Entrez	347240

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000379174, ENST00000402558, ENST00000684219, ENST00000911288, ENST00000911290, ENST00000911291

RefSeq mRNA: 1 — MANE Select: NM_194313 NM_194313

CCDS: CCDS6551

Canonical transcript exons

ENST00000402558 — 13 exons

Exon	Start	End
ENSE00001379669	34255072	34255165
ENSE00001388363	34255735	34257981
ENSE00001597400	34290174	34290389
ENSE00001606085	34269257	34269362
ENSE00001617010	34271809	34271930
ENSE00001662467	34259596	34259705
ENSE00001682992	34263101	34263172
ENSE00001701045	34306252	34306441
ENSE00001769105	34297017	34297114
ENSE00001787244	34286617	34286704
ENSE00002323872	34310724	34311371
ENSE00003919348	34252380	34254520
ENSE00003919747	34329106	34329268

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 83.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.8508 / max 76.2733, expressed in 1145 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100493	3.8508	1145

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.73	gold quality
ventricular zone	UBERON:0003053	80.91	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.75	gold quality
testis	UBERON:0000473	75.83	gold quality
right testis	UBERON:0004534	75.40	gold quality
left testis	UBERON:0004533	75.28	gold quality
right uterine tube	UBERON:0001302	73.82	gold quality
ganglionic eminence	UBERON:0004023	73.47	gold quality
stromal cell of endometrium	CL:0002255	70.61	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	68.69	gold quality
bone marrow cell	CL:0002092	66.74	silver quality
bone marrow	UBERON:0002371	66.32	gold quality
fallopian tube	UBERON:0003889	63.50	gold quality
placenta	UBERON:0001987	61.87	gold quality
endometrium	UBERON:0001295	61.26	gold quality
smooth muscle tissue	UBERON:0001135	61.00	gold quality
vermiform appendix	UBERON:0001154	60.80	gold quality
rectum	UBERON:0001052	60.74	gold quality
right adrenal gland cortex	UBERON:0035827	60.55	gold quality
right adrenal gland	UBERON:0001233	60.31	gold quality
mucosa of transverse colon	UBERON:0004991	60.30	gold quality
lymph node	UBERON:0000029	59.63	gold quality
colonic epithelium	UBERON:0000397	59.59	gold quality
tonsil	UBERON:0002372	59.55	gold quality
gastrocnemius	UBERON:0001388	59.54	gold quality
muscle tissue	UBERON:0002385	59.53	gold quality
muscle of leg	UBERON:0001383	59.22	gold quality
nucleus accumbens	UBERON:0001882	59.07	gold quality
skeletal muscle tissue	UBERON:0001134	58.79	gold quality
esophagus mucosa	UBERON:0002469	58.52	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.08

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

115 targeting KIF24, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515

Literature-anchored findings (GeneRIF, showing 4)

• KIF24 rs17350674 polymorphism likely acts as a risk factor for sporadic Lobar Degeneration (PMID:20670673)
• Study found that loss of Kif24 leads to the disappearance of CP110 from mother centrioles in cycling cells able to form cilia; thus, identifying a centriolar kinesin that specifically remodels a subset of microtubules, thereby regulating cilia assembly. (PMID:21620453)
• Kif24 is a physiological substrate of Nek2, which regulates cilia disassembly through a concerted mechanism involving Kif24-mediated microtubule depolymerization. (PMID:26290419)
• Biallelic KIF24 Variants Are Responsible for a Spectrum of Skeletal Disorders Ranging From Lethal Skeletal Ciliopathy to Severe Acromesomelic Dysplasia. (PMID:35748595)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Kif24	ENSMUSG00000028438
rattus_norvegicus	Kif24	ENSRNOG00000012735
drosophila_melanogaster	Klp10A	FBGN0030268
drosophila_melanogaster	Klp59C	FBGN0034824
drosophila_melanogaster	Klp59D	FBGN0034827
caenorhabditis_elegans		WBGENE00002219

Paralogs (41): KIF1B (ENSG00000054523), KIF26A (ENSG00000066735), KIF2A (ENSG00000068796), KIF22 (ENSG00000079616), KIF3C (ENSG00000084731), KIF9 (ENSG00000088727), KIF16B (ENSG00000089177), KIF4A (ENSG00000090889), KIF3B (ENSG00000101350), KIF20A (ENSG00000112984), KIF21B (ENSG00000116852), KIF17 (ENSG00000117245), KIF14 (ENSG00000118193), KIF18A (ENSG00000121621), KIF25 (ENSG00000125337), KIF1C (ENSG00000129250), KIF1A (ENSG00000130294), KIF3A (ENSG00000131437), KIF12 (ENSG00000136883), KIF13A (ENSG00000137177), KIF23 (ENSG00000137807), KIF11 (ENSG00000138160), CENPE (ENSG00000138778), KIF21A (ENSG00000139116), KIFC3 (ENSG00000140859), KIF2B (ENSG00000141200), KIF2C (ENSG00000142945), KIF5A (ENSG00000155980), KIF26B (ENSG00000162849), KIF15 (ENSG00000163808), KIF6 (ENSG00000164627), KIF27 (ENSG00000165115), KIF7 (ENSG00000166813), KIFC2 (ENSG00000167702), KIF5C (ENSG00000168280), KIF5B (ENSG00000170759), KIF18B (ENSG00000186185), KIF19 (ENSG00000196169), KIF13B (ENSG00000197892), KIF4B (ENSG00000226650)

Protein

Protein identifiers

Kinesin-like protein KIF24 — Q5T7B8 (reviewed: Q5T7B8)

All UniProt accessions (2): A0A804HHR8, Q5T7B8

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule-dependent motor protein that acts as a negative regulator of ciliogenesis by mediating recruitment of CCP110 to mother centriole in cycling cells, leading to restrict nucleation of cilia at centrioles. Mediates depolymerization of microtubules of centriolar origin, possibly to suppress aberrant cilia formation. Following activation by NEK2 involved in disassembly of primary cilium during G2/M phase but does not disassemble fully formed ciliary axonemes. As cilium assembly and disassembly is proposed to coexist in a dynamic equilibrium may suppress nascent cilium assembly and, potentially, ciliar re-assembly in cells that have already disassembled their cilia ensuring the completion of cilium removal in the later stages of the cell cycle. Plays an important role in recruiting MPHOSPH9, a negative regulator of cilia formation to the distal end of mother centriole.

Subunit / interactions. Interacts with CCP110, CEP97, TALPID3. Interacts with MPHOSPH9.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Kinesin family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q5T7B8-1	1	yes
Q5T7B8-2	2
Q5T7B8-3	3
Q5T7B8-4	4

RefSeq proteins (1): NP_919289* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001660	SAM	Domain
IPR001752	Kinesin_motor_dom	Domain
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR019821	Kinesin_motor_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR027640	Kinesin-like_fam	Family
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily

Pfam: PF00225, PF00536

UniProt features (45 total): region of interest 11, modified residue 10, compositionally biased region 7, sequence variant 6, splice variant 4, mutagenesis site 3, domain 2, chain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T7B8-F1	52.18	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 313–320

Post-translational modifications (10): 102, 112, 478, 584, 621, 622, 646, 826, 829, 1012

Mutagenesis-validated functional residues (3):

Position	Phenotype
263–264	impairs ability to suppress cilia formation.
483–485	impairs ability to suppress cilia formation.
621–622	reduces phosphorylation by nek2 and abolishes ability to suppress cilia formation.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5620912	Anchoring of the basal body to the plasma membrane
R-HSA-1852241	Organelle biogenesis and maintenance
R-HSA-5617833	Cilium Assembly

MSigDB gene sets: 111 (showing top): GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_NEGATIVE_REGULATION_OF_ORGANELLE_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_MICROTUBULE_DEPOLYMERIZATION, GOBP_CILIUM_ORGANIZATION, chr9p13, GOMF_CYTOSKELETAL_MOTOR_ACTIVITY, GOCC_CENTROSOME, GOBP_ORGANELLE_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_PROTEIN_DEPOLYMERIZATION, FISCHER_DREAM_TARGETS

GO Biological Process (5): microtubule-based movement (GO:0007018), microtubule depolymerization (GO:0007019), cilium assembly (GO:0060271), negative regulation of cilium assembly (GO:1902018), cell projection organization (GO:0030030)

GO Molecular Function (6): microtubule motor activity (GO:0003777), ATP binding (GO:0005524), microtubule binding (GO:0008017), identical protein binding (GO:0042802), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (7): centrosome (GO:0005813), centriole (GO:0005814), cytosol (GO:0005829), microtubule (GO:0005874), protein-containing complex (GO:0032991), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Assembly of the 9+0 primary cilium	1
Organelle biogenesis and maintenance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
microtubule organizing center	2
intracellular membraneless organelle	2
cellular anatomical structure	2
microtubule-based process	1
microtubule polymerization or depolymerization	1
protein depolymerization	1
supramolecular fiber organization	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
cilium assembly	1
negative regulation of plasma membrane bounded cell projection assembly	1
regulation of cilium assembly	1
negative regulation of organelle assembly	1
cellular component organization	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
ATP-dependent activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
tubulin binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
centriole	1
cytoplasm	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
cellular_component	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1330 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KIF24	CCP110	O43303	886
KIF24	CEP97	Q8IW35	861
KIF24	CEP290	O15078	677
KIF24	TTBK2	Q6IQ55	606
KIF24	NEK2	P51955	599
KIF24	CEP164	Q9UPV0	572
KIF24	HDAC6	Q9UBN7	556
KIF24	UBAP1	Q9NZ09	528
KIF24	KIAA0586	Q9BVV6	507
KIF24	CEP104	O60308	501
KIF24	CEP83	Q9Y592	481
KIF24	SPATA9	Q9BWV2	459
KIF24	ARL13B	Q3SXY8	459
KIF24	CIMAP3	Q8TCI5	452
KIF24	PLK1	P53350	449

IntAct

35 interactions, top by confidence:

A	B	Type	Score
CEP97	CCP110	psi-mi:“MI:0914”(association)	0.950
KIF24	CCP110	psi-mi:“MI:0914”(association)	0.810
KIF24	CCP110	psi-mi:“MI:0915”(physical association)	0.810
KIF24	CEP97	psi-mi:“MI:0915”(physical association)	0.810
CCP110	KIF24	psi-mi:“MI:0914”(association)	0.810
CEP76	CEP290	psi-mi:“MI:0914”(association)	0.740
CEP97	CEP290	psi-mi:“MI:0914”(association)	0.740
KIF24	NEK2	psi-mi:“MI:0915”(physical association)	0.620
NEK2	KIF24	psi-mi:“MI:0217”(phosphorylation reaction)	0.620
NEK2	KIF24	psi-mi:“MI:0403”(colocalization)	0.620
KIAA0586	CCP110	psi-mi:“MI:0914”(association)	0.560
KIF24	KIF24	psi-mi:“MI:0915”(physical association)	0.540
KIF24	KIF24	psi-mi:“MI:1126”(self interaction)	0.540
Cdk1		psi-mi:“MI:0915”(physical association)	0.400
Plk1		psi-mi:“MI:0915”(physical association)	0.400

BioGRID (48): KIF24 (Two-hybrid), JAK1 (Affinity Capture-MS), CEP97 (Affinity Capture-MS), DOT1L (Affinity Capture-MS), RPS19BP1 (Affinity Capture-MS), KIF24 (Affinity Capture-MS), KIF24 (Affinity Capture-MS), KIF24 (Affinity Capture-MS), KIF24 (Affinity Capture-RNA), KIF24 (Two-hybrid), KIF24 (Two-hybrid), KIF24 (Two-hybrid), KIF24 (Two-hybrid), KIF24 (Two-hybrid), KIF24 (Two-hybrid)

ESM2 similar proteins: A0JM98, A1L1H3, A4Q9E8, A4Q9F0, A4Q9F6, A6NNM8, A7MBJ2, A8CVX7, D3ZF42, O54928, O75159, O88866, P51957, P57058, P59110, Q08D35, Q0P4M4, Q14679, Q29RN6, Q5NC05, Q5QJC4, Q5R978, Q5RHD1, Q5SUS0, Q5T7B8, Q63679, Q68UT7, Q6EEF3, Q6EMB2, Q6GQJ2, Q6IE81, Q6IE82, Q6IRU7, Q6NWW5, Q6P1H6, Q6P7W0, Q6PCM1, Q6PJP8, Q6ZPI0, Q7TP65

Diamond homologs: A0A068FIK2, A1ZAJ2, A6H750, A8BKD1, B7EJ91, B7ZNG0, B9EY52, B9F2Y7, B9F7C8, B9FMJ3, E2RTQ2, F1M4A4, F4ICA0, F4IIS5, F4K0J3, L0N7N1, O00139, O14343, O15066, O23826, O35071, O35787, O43896, O45935, O59751, O60282, O95239, P21613, P23678, P28740, P28741, P33173, P33174, P33176, P46863, P46867, P46874, P53086, P70096, P82266

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NEK2	“up-regulates activity”	KIF24	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

224 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	174
Likely benign	18
Benign	12

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1217223	NM_194313.4(KIF24):c.1565A>G (p.Asn522Ser)	Pathogenic
1328460	GRCh37/hg19 9p13.3(chr9:34196100-34261664)x1	Pathogenic

SpliceAI

2642 predictions. Top by Δscore:

Variant	Effect	Δscore
9:34255070:A:AC	donor_gain	1.0000
9:34255071:C:CT	donor_gain	1.0000
9:34255071:CA:C	donor_gain	1.0000
9:34259593:T:TG	donor_loss	1.0000
9:34259594:A:AC	donor_gain	1.0000
9:34259594:AC:A	donor_gain	1.0000
9:34259595:C:CG	donor_gain	1.0000
9:34259595:CC:C	donor_gain	1.0000
9:34259595:CCG:C	donor_gain	1.0000
9:34259595:CCGG:C	donor_gain	1.0000
9:34259595:CCGGT:C	donor_gain	1.0000
9:34259701:AGGAC:A	acceptor_gain	1.0000
9:34259702:GGAC:G	acceptor_gain	1.0000
9:34259703:GAC:G	acceptor_gain	1.0000
9:34259704:AC:A	acceptor_gain	1.0000
9:34259705:CC:C	acceptor_gain	1.0000
9:34259705:CCTG:C	acceptor_loss	1.0000
9:34259706:C:A	acceptor_loss	1.0000
9:34259706:C:CC	acceptor_gain	1.0000
9:34259707:T:A	acceptor_loss	1.0000
9:34259711:C:CT	acceptor_gain	1.0000
9:34259711:C:T	acceptor_gain	1.0000
9:34259712:A:T	acceptor_gain	1.0000
9:34259716:C:CT	acceptor_gain	1.0000
9:34259717:A:T	acceptor_gain	1.0000
9:34269255:A:AC	donor_gain	1.0000
9:34269256:C:CC	donor_gain	1.0000
9:34269256:CAG:C	donor_gain	1.0000
9:34271803:GCTCA:G	donor_loss	1.0000
9:34271804:CTCA:C	donor_loss	1.0000

AlphaMissense

9002 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:34259596:C:G	R542P	0.999
9:34263122:G:C	F498L	0.999
9:34263122:G:T	F498L	0.999
9:34263124:A:G	F498L	0.999
9:34263154:C:G	A488P	0.999
9:34263156:C:G	R487P	0.999
9:34263167:C:A	K483N	0.999
9:34263167:C:G	K483N	0.999
9:34263171:A:G	L482P	0.999
9:34269261:A:G	L480P	0.999
9:34269264:A:G	L479P	0.999
9:34269266:A:C	S478R	0.999
9:34269266:A:T	S478R	0.999
9:34269268:T:G	S478R	0.999
9:34269345:A:G	L452S	0.999
9:34306379:C:G	R229P	0.999
9:34306382:A:T	V228D	0.999
9:34259602:G:T	A540D	0.998
9:34259608:C:G	R538P	0.998
9:34259620:A:G	L534P	0.998
9:34259659:G:T	A521D	0.998
9:34259701:A:G	L507P	0.998
9:34263113:G:C	S501R	0.998
9:34263113:G:T	S501R	0.998
9:34263115:T:G	S501R	0.998
9:34263120:C:A	R499M	0.998
9:34263120:C:G	R499T	0.998
9:34269276:A:T	I475K	0.998
9:34269335:A:C	S455R	0.998
9:34269335:A:T	S455R	0.998

dbSNP variants (sampled 300 via entrez): RS1000015497 (9:34326798 G>A), RS1000029224 (9:34287586 A>C), RS1000100338 (9:34278461 C>A), RS1000120988 (9:34285584 C>A,T), RS1000156318 (9:34327218 G>A), RS1000162852 (9:34285188 TTAA>T), RS1000203599 (9:34291375 C>T), RS1000272276 (9:34333381 C>G,T), RS1000272854 (9:34307958 T>C), RS1000362392 (9:34297500 C>T), RS1000383992 (9:34270905 C>G), RS1000409862 (9:34332807 A>C), RS1000425278 (9:34284851 C>T), RS1000480790 (9:34331370 T>C), RS1000518675 (9:34289736 T>C)

Disease associations

OMIM: gene MIM:613747 | disease phenotypes: MIM:613091

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (3): asphyxiating thoracic dystrophy 3 (MONDO:0013127), peripheral neuropathy (MONDO:0005244), schizophrenia (MONDO:0005090)

Orphanet (4): Jeune syndrome (Orphanet:474), Short rib-polydactyly syndrome, Majewski type (Orphanet:93269), Short rib-polydactyly syndrome, Saldino-Noonan type (Orphanet:93270), Short rib-polydactyly syndrome, Verma-Naumoff type (Orphanet:93271)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008789_7	Adolescent idiopathic scoliosis	2.000000e-09
GCST010136_34	Fruit consumption	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008111	diet measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537602	Short rib-polydactyly syndrome, Verma-Naumoff type (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3879840 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	decreases expression, decreases methylation	3
sodium arsenite	increases abundance, increases expression, affects cotreatment, decreases expression	2
(+)-JQ1 compound	decreases expression, affects cotreatment	2
Cisplatin	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
propionaldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
coumarin	affects phosphorylation	1
polyhexamethyleneguanidine	affects expression	1
CGP 52608	increases reaction, affects binding	1
abrine	increases expression	1
mirdametinib	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Troglitazone	decreases expression	1
Acetaminophen	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Calcitriol	decreases expression, affects cotreatment	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
N-Nitrosopyrrolidine	decreases expression	1
Oxygen	decreases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	decreases expression, affects cotreatment	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Acrylamide	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3860194	Binding	Inhibition of basal ATPase activity of human Kif24 at 200 uM by pyruvate kinase/lactate dehydrogenase-linked assay	Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis. — J Nat Prod

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9HZ	Ubigene HEK293 KIF24 KO	Transformed cell line	Female

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety